the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Leukemia Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
IRB16-1614 Thirman, Michael A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy Details
IRB16-1712 Stock, Wendy A Phase III, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia Details
IRB16-0378 Larson, Richard A Phase II/III Multicenter, Open-Label, 3-Arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib),Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy Details
IRB16-0127 Larson, Richard A Phase III, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First) Details
IRB15-1167 Larson, Richard A Phase III, Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation Details
IRB15-0678 Larson, Richard A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Details
CIRB14-1502 McNeer, Jennifer AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) Details
CIRB14-1184 McNeer, Jennifer COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy) Details
10-617-A McNeer, Jennifer COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) Details
Phase II
Study No PI Title
IRB15-0840 Stock, Wendy Phase 1b/2 Study of Entospletinib (GS 9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML) Details
IRB16-0378 Larson, Richard A Phase II/III Multicenter, Open-Label, 3-Arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib),Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy Details
IRB15-1622 Odenike, Olatoyosi A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy Details
IRB15-1147 Bishop, Michael A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) Details
IRB15-1373 Odenike, Olatoyosi Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients with Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Details
CIRB15-0185 Liu, Hongtao Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy Details
IRB14-0702 Odenike, Olatoyosi A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS) Details
Phase I
Study No PI Title
IRB15-0840 Stock, Wendy Phase 1b/2 Study of Entospletinib (GS 9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML) Details
IRB16-0371 Stock, Wendy A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of Xmab14045 in Patients with CD123-Expressing Hematologic Malignancies Details
IRB15-1622 Odenike, Olatoyosi A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy Details
IRB15-1147 Bishop, Michael A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) Details
IRB15-1460 Odenike, Olatoyosi A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation Details
IRB15-1373 Odenike, Olatoyosi Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients with Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Details
IRB15-1459 Stock, Wendy A Phase 1, Open-label, Adaptive Dose escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT 402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Details
IRB15-1285 Stock, Wendy A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects with Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Details
IRB15-0115 Stock, Wendy A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973)with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL) Details
IRB14-0702 Odenike, Olatoyosi A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS) Details
IRB14-0651 Thirman, Michael A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are Older than 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy Details
IRB13-0858 Larson, Richard A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (ERYASP) in Combination with the CALGB Regimen During Induction and Consolidation Phases for Frontline Therapy of Subjects Older than 40 Years with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Details
IRB17-0633 Stock, Wendy A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed Acute Lymphoblastic Leukemia
Others
Study No PI Title
IRB17-0086 Larson, Richard A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3 Mutated AML in Complete Remission (CR) with Minimal Residual Disease (MRD) Details
CIRB17-0228 Stock, Wendy M1 - A Master Protocol for Biomarker-Based Treatment of AML Details
11-0014 Godley, Lucy Evaluation of patients with hematopoietic malignancies and their family members for mutations in RUNX1, CEBPA, and p53.
10-586-A McNeer, Jennifer COG AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia Details
10-064-B Godley, Lucy Molecular characterization of hematopoietic malignancies
09-130-B Stock, Wendy A University of Chicago Leukemia Registry Protocol.
16070A McNeer, Jennifer A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens Details
4186 Larson, Richard Etiology Of Alkylator-Induced Myeloid Leukemia


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .